Page 1,612«..1020..1,6111,6121,6131,614..1,6201,630..»

Organogenesis Shares Successes and Best Practices for Cell-Based Product Manufacturing at the 6th Stem Cell … – Yahoo Finance

Posted: April 6, 2017 at 8:48 pm

CANTON, Mass., April 6, 2017 /PRNewswire/ --Stem cell scientists, researchers and product developers will learn more about Organogenesis' state-of-the art manufacturing process and successful commercial-scale production of FDA-approved wound healing therapies at the 6th Stem Cell Product Development and Commercialization Conference held April 6-7 in Boston, Massachusetts. The conference highlights cutting-edge developments in all areas of stem cell research, including the biology, medicine, applications and regulation of stem cells.

Zorina Pitkin, PhD, Senior Vice President of Quality for Organogenesis, will participate in an expert panel to discuss Apligraf and Dermagraft, two bioengineered, living cell-based therapies that are produced on a commercial scale by Organogenesis. The presentation will cover the Apligraf manufacturing process and highlight the important role of keratinocyte stem cells in functional Apligraf product.

Apligraf (manufactured near the conference, in Canton, MA), and Dermagraft (manufactured in San Diego, CA), are FDA-approved Class III medical devices indicated for the treatment of diabetic foot ulcers. Apligraf is also indicated for the treatment of venous leg ulcers. More than 1 million units of the products have been shipped to date.

"One of the challenges we see with cell-based manufacturing is the transition from pilot to commercial scale production and the ability to perform large scale manufacturing at a low cost," said Dr. Pitkin. "At Organogenesis, we've achieved this successfully through process optimization and product consistency that includes multiple levels of quality control and safety."

In Apligraf, keratinocyte stem cells are required to form the product's differentiated epidermis and provide increased levels of growth factors and cytokines, so it is vital that these cells are preserved through the manufacturing, shipping and distribution process. Through a scale-up manufacturing process that creates a three-dimensional bi-layered construct, Organogenesis is able to produce a bioengineered product with living cells on a consistent basis that delivers a therapeutic benefit to patients with hard-to-heal wounds.

"With five million Americans affected by diabetic foot ulcers and venous leg ulcers, it's crucial that we consistently produce and manufacture safe, reliable products that promote healing," added Dr. Pitkin. "Organogenesis is at the forefront of this effort, having developed a successful and reliable manufacturing process."

The 6th Stem Cell Product Development and Commercialization Conference presents information regarding cutting-edge developments in all areas of stem cell research, including the biology, medicine, applications and regulation of stem cells. Topics of discussion include recent developments in pre-clinical and clinical trials of stem cell therapy, regenerative medicine and tissue engineering, cancer stem cells, immunotherapy, stem cell reprogramming, and regulatory policies regarding stem cell research.

About Organogenesis Inc.Headquartered in Canton, Massachusetts, Organogenesis Inc. is a global leader in regenerative medicine, offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis' versatile portfolio is designed to treat a variety of patients with repair and regenerative needs. For more information, visit http://www.organogenesis.com.

CONTACT:Angelyn Lowe (781) 830-2353 alowe@organo.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/organogenesis-shares-successes-and-best-practices-for-cell-based-product-manufacturing-at-the-6th-stem-cell-product-development-and-commercialization-conference-300436140.html

Read more:
Organogenesis Shares Successes and Best Practices for Cell-Based Product Manufacturing at the 6th Stem Cell ... - Yahoo Finance

Posted in Cell Medicine | Comments Off on Organogenesis Shares Successes and Best Practices for Cell-Based Product Manufacturing at the 6th Stem Cell … – Yahoo Finance

Stem Cell Therapy for Autism Shows Promise – WebMD

Posted: April 6, 2017 at 8:47 pm

April 6, 2017 -- A stem cell treatment for autism shows promise, according to a new study, but the investigators and other experts emphasize that the therapy is still in the early stages and much more research is needed.

The Duke University study included 25 children, ages 2-6, with autism and assessed whether a transfusion of the youngsters' own umbilical cord blood containing rare stem cells would help treat their autism, CNN reported.

Behavioral improvements were reported in 70 percent of the patients, according to the study in the journal Stem Cells.

A second, larger trial is now underway and the researchers hope they will find a long-term treatment for autism, CNN reported.

Some experts say many unanswered questions remain and the study authors agree much more work needs to be done. This initial trial was a safety study, meaning doctors and the children's families knew the therapy was being administered and there was no comparison between treated and non-treated children.

"Some children, who were not speaking very much, had big increases in their vocabulary and their functional speech," study author Dr. Joanne Kurtzberg, head of the Robertson Clinical and Translational Cell Therapy Program, told CNN.

"Many children were able to attend to play and have meaningful communication in a way that they weren't before. Some children had less repetitive behaviors than they did when they came onto the study," Kurtzberg said.

"The study was very encouraging. We did see positive results. However, it did not have a comparison group, which is very important in establishing whether a treatment is actually effective," study author Dr. Geraldine Dawson, director of the Duke Center for Autism and Brain Development, told CNN.

WebMD News from HealthDay

Read more here:
Stem Cell Therapy for Autism Shows Promise - WebMD

Posted in Cell Therapy | Comments Off on Stem Cell Therapy for Autism Shows Promise – WebMD

Evotec and Sanofi Hit the First Milestone for a Diabetes Cell Therapy – Labiotech.eu (blog)

Posted: April 6, 2017 at 8:47 pm

Evotec and Sanofi have achieved preclinical proof-of-concept for a new beta cell therapy for diabetes, triggering a 3M milestone payment from Sanofi.

In 2015, Sanofi and the German CRO Evotecpartnered to jointly develop a beta cell replacement therapy for the treatment of diabetes in a deal that could reach more then 300Min potential milestone payments. Today, the first one arrived as Evotec received 3M for itsfirst preclinical success.

The new cell therapy will be based onfunctional beta cells, which are derived from human stem cells. These beta cells could not only serve as abeta cell replacement, but also ahigh-throughput drug screening platformto identify small molecules or biologicsbeneficial for beta cell activity.

Beta cells play a key role in pathogenesis of diabetes, an epidemic disease, which currently affects about 422M people worldwide.They reside within the pancreas and respond to elevated blood levels by secreting the glucose lowering hormone insulin.While in type 1 diabetes, beta cellsare destroyed by the patients own immune system, in type 2 diabetes these cells often become functionally impaired.

Given thepersistent need for new treatment opportunities and the incredible market opportunity, cell therapy for diabetes has become a popular field of research.Just recently, scientists from the Diabetes Research Institute (DRI) at the University of Miami have cured the first patient from diabetes after implantation of a bioengineered mini organ that mimics the native pancreas. The DRI Biohub is currently in Phase I/II studies.

Other companies such as British Islexa are working on reprogramming thepancreatic cells into functional islets for transplantation. Belgian Orgenesis uses the patients own liver cells and aims to convert these into functional insulin producing cells. The company has completed preclinical safety and efficacy studies and is currently planning to move into the clinic.

Eventually cell therapy approaches could obviatethe need to follow a life-long regimen of insulin injections, which often cannot fully prevent the long-term complications of high blood sugar.

However, Evotec and Sanofi are not only facing a crowded market, but the technology is also still in its infancy. In light of the high costs and safety risks of cell therapies, the new approaches will still have to prove that they can hold up to what they are promising.

You can read more about whats going on in the diabetes field in our recent review.

Images viaSyda ProductionsandDesignua / shutterstock.com

Continued here:
Evotec and Sanofi Hit the First Milestone for a Diabetes Cell Therapy - Labiotech.eu (blog)

Posted in Cell Therapy | Comments Off on Evotec and Sanofi Hit the First Milestone for a Diabetes Cell Therapy – Labiotech.eu (blog)

T-cell Therapy for Ovarian Cancer Shows Promise | Technology … – Technology Networks

Posted: April 6, 2017 at 8:47 pm

In this photo, mouse ovarian cancer cells light up with different proteins targeted by the engineered T cells. Image by Kristin Anderson and Ingunn Stromnes / Greenberg Lab

For some patients, certain forms of immunotherapy are showing promise in treating previously difficult-to-treat cancers. In the case of T-cell therapies, though, most of the early experimental successes have been seen in blood cancers. Solid tumors, like breast, lung, ovarian and pancreatic cancers, pose a tougher nut to crack for this new wave of cancer therapies.

Fred Hutchinson Cancer Research Center immunotherapy researchers Drs. Kristin Anderson and Phil Greenberg and their colleagues are working on ways to tweak their teams early successes with T-cell therapy for leukemia to apply to solid tumors. In a presentation Tuesday at the annual meeting of the American Association of Cancer Research in Washington, D.C., Anderson described her preclinical results working toward T-cell therapy for ovarian tumors and the hurdles any clinical version of this therapy will need to overcome. To date, the therapies Anderson and her colleagues are developing have only been tested in mice and in mouse and human cells in the lab.

Developing T-cell therapy for solid tumors is more challenging than for leukemias and lymphomas, Anderson said, but many patients with these cancers are in desperate need of new treatment options. The top five cancer killers in the U.S. are all solid tumors, according to the American Cancer Society. Although ovarian cancer is less common in the U.S. than other solid cancers, its highly deadly it tends to be diagnosed at late stages, in part because it often doesnt cause obvious symptoms, and it has a high relapse rate, Anderson said.

All of these are huge problems, she said. An estimated 22,000 women in the U.S. are diagnosed per year with the disease, according to the ACS, and approximately 14,000 die of the cancer.

The challenges of T-cell therapy for cancers like ovarian cancer include the simple issue of access patients with leukemia or lymphoma can receive an infusion of engineered T cells directly into their bloodstream, but it can be more difficult to tweak the cells to traffic to a tumor tucked away in the body. Another major roadblock to adopting T-cell therapy to solid tumors is whats known as the tumor microenvironment, the local milieu of non-cancerous cells and molecules in and around the tumor.

Tumor microenvironment issues come hand-in-hand with working on solid tumors, said Anderson, who is one of 10 recipients of this years AACR Women in Cancer Research Scholar Awards, a travel award given to female early-career cancer researchers presenting at the meeting.

She and her colleagues have identified proteins overproduced by ovarian cancer cells, known as WT1 and mesothelin, and have found that T cells engineered to specifically recognize these proteins can kill both human and mouse ovarian cancer cells in the lab. Theyve also found that the T cells significantly extend survival in a mouse model of the cancer, but theres a ways to go before this therapy is ready for clinical trials in humans, Anderson said.

In her presentation, Anderson outlined three types of tumor microenvironment roadblocks to an effective ovarian cancer T-cell therapy and how the research team is working to overcome each. They are:

Immunosuppressive cells and proteins in the microenvironment that can signal the engineered T cells to shut down or ignore tumors. Existing checkpoint inhibitor drugs could circumvent this problem, Anderson said, and the Fred Hutch team is also exploring engineering the therapeutic T cells to block those immunosuppressive signals.

A death signal produced by both ovarian tumor cells and nearby blood vessels on their surfaces. This molecular signal causes T cells heading to the tumor from the bloodstream to commit suicide before they can fight the cancer. Dr. Shannon Oda in the Greenberg lab is working on a new type of fusion protein the engineered T cells will carry that will rewire their internal circuitry to instead boost their anti-tumor activity in response to the death signal.

The tumors low-sugar environment. Fast-growing ovarian cancer cells churn through the glucose in their environment the same energy source engineered T cells need to do their work. Researchers in the Greenberg lab are working to re-engineer the therapeutic T cells to process other sources of energy.

Although her current work focuses on ovarian cancer, a particularly difficult-to-treat solid tumor, Anderson hopes the work will shed light on new therapeutic avenues for other solid tumors as well.

If we can solve some of the issues that really plague us with these hard ones, then we can more readily apply [the solutions] to cancers that have fewer of these hurdles, she said.

The researchers are hoping to launch a clinical trial of the engineered T cells for patients with ovarian cancer in the next few years, Anderson said.

Paying it forward

For Anderson, the work is not just academic. Five years ago, while she was completing her doctorate research, Anderson was diagnosed with triple negative breast cancer when she was just 28. After her diagnosis, she learned she carried a mutation in the breast cancerlinked gene BRCA1, a mutation which also increases her risk for ovarian cancer.

An immunologist by training, Andersons own experience with cancer spurred her to look for research opportunities where she could one day have a direct impact on other cancer patients. She wasnt particularly looking to study breast or ovarian cancer, she said, but she was very interested in the burgeoning field of immunotherapy. It seemed a prime research area where she could use her background to make a difference.

When Anderson met with Greenberg, whos long been a leader in the field of T-cell therapy, to discuss research options for her postdoctoral fellowship, he proposed the ovarian cancer project to her. Anderson jumped at the chance.

Someone did a lot of research to come up with the drug that got rid of my cancer. Part of the reason that I wanted to go into cancer therapy was so I could pay it forward and do that for someone else, she said. It just so happened coincidentally to be [a cancer] that is close to my heart.

Read this article:
T-cell Therapy for Ovarian Cancer Shows Promise | Technology ... - Technology Networks

Posted in Cell Therapy | Comments Off on T-cell Therapy for Ovarian Cancer Shows Promise | Technology … – Technology Networks

Diabetes Partnership to dissolve – Cleveland Jewish News

Posted: April 6, 2017 at 8:46 pm

The Diabetes Partnerships board of directors voted to dissolve the organization April 5, and began efforts to launch two groups to operate Camp Ho Mita Koda, the annual diabetes summer camp for children, and community programs that distribute insulin and ongoing diabetes self-management education.

Members of the board cited changes in the national healthcare landscape, the evolving needs of people with diabetes and the costs of owning and operating the camp in Newbury, according to a news release.

In effect, were going out of business, said William Murman, board chairman, in the release. Its a sad day for all of us who have dedicated our time and talents to this cause. But we know that in this case, the most difficult step can be the right step in finding a better way forward.

Two separate meetings are scheduled, one for those interested in saving and operating the summer programs at Camp Ho Mita Koda, and one for those interested in saving and operating the community programs. The meeting for the camp will be at 7 p.m. April 24 at Camp Ho Mita Koda, 14040 Auburn Road in Newbury. The meeting for the community programs will be at 7 p.m. April 18 at the Diabetes Partnership office, 3601 S. Green Road.

Anyone with questions about the programs or summer camp can call Tom Bennett, executive director of the Diabetes Partnership, at 216-591-0800 or email tbennett@diabetespartnership.org.

Visit link:
Diabetes Partnership to dissolve - Cleveland Jewish News

Posted in Diabetes | Comments Off on Diabetes Partnership to dissolve – Cleveland Jewish News

Purdue Extension offers "Dining with Diabetes" program – Washington Times Herald

Posted: April 6, 2017 at 8:46 pm

Do you have Type 2 Diabetes? Would you like to learn more about your disease and how to live well reducing your health risks? If so, Purdue Extension has a great program for you!

The Purdue Extension-Knox County office, in partnership with the Daviess County Purdue Extension Service, offers four two-hour sessions that will be held from 5 p.m. to 7 p.m. on each Thursday during May with the first session scheduled on May 4 and the fourth session on May 25. Participants may also elect to have a follow-up session in June. The Dining with Diabetes program is open to those with diabetes, their family members and caretakers. The series of four sessions is $25/person or $35/couple. Pre-registration and payment is required no later than April 28. Participants are encouraged to attend all class sessions which will be held at the Knox County Extension Office, 4259 N. Purdue Road in Vincennes.

The educational programs and cooking school will help adults with type 2 diabetes control their blood sugar, to feel better, and reduce their risk of health complications. Those enrolling will learn how to prepare meals that are healthy, easy to prepare and taste good. Recipes will be demonstrated, and participants will have the opportunity to taste each one. Participants will also learn up-to-date information on nutrition, meal planning, exercise and how to understand common diabetes-related medical tests. Recipe and handouts will be given to each participant.

Diabetes is a very serious and costly disease, but research has shown that those who learn to manage their blood glucose (sugar) levels, eat a healthy diet and exercise regularly can lower their risks of complications and lead a healthier and more productive life.

Purdue Extension Knox County and Daviess County are currently recruiting participants for this program. If you have been diagnosed with type 2 diabetes, or know someone and are part of the support system for an individual and are interested in being a part of this program, please call the Purdue Extension office at 812-882-3509. Registration and program fee may be sent to: 4259 N. Purdue Road by April 28. The $25/$35 program fee includes educational classes, program materials and food sampling. Dining with Diabetes is offered statewide and is sponsored by Purdue Extension.

Read more:
Purdue Extension offers "Dining with Diabetes" program - Washington Times Herald

Posted in Diabetes | Comments Off on Purdue Extension offers "Dining with Diabetes" program – Washington Times Herald

Depression and diabetes – The Hippocratic Post (blog)

Posted: April 6, 2017 at 8:46 pm

To mark the WHOs World Health Day 2017 which, this year, focuses on depression, we talk to Robin Hewings, head of policy for the charity Diabetes UK.

People with diabetes are twice as likely to suffer from depressionthanthe average adult living in the UK andmay also have depressive periods for longer than those without diabetes, but it is an issue that is often ignored or forgotten because the clinical priority is seen to be stabilisation and management of blood sugar levels.Having depression could also have a knock-on effect on how well diabetes is controlled.

Although depression is not a clinical symptom of diabetes,it could be the result of a variety of factors such as coming to terms with a diagnosis, dealing with the day to day responsibility of managing diabetes or the development of a diabetes-related complication.

People with Type 1 diabetes, which often begins in childhood and happens because the body cannot produce insulin, may simply feel demoralised by the day-in, day-out regime of keeping on top of their blood sugar levels. Someone with Type 1may need to test their blood sugar levels several times a dayas well asdoses of insulinthroughout the dayeither as an injection or via a pump.Episodesof hypoglyaceamia (low blood sugar) can leavesome people with diabetesfeeling a like a failure as well as physically exhausted during the recovery period.

Around3.6million peopleare now diagnosed withdiabetes in the UK, and 90 per cent of them have type 2 diabetes, which islinked to obesity and usually occurs in adulthood. For them, the diagnosis itself may be a shock whichin turn could lead to depression.They may struggle to lose weight and take up regular exercise and so lose confidence in themselves and their ability to manage the condition.

The very serious complicationsof diabetes, including blindness, kidney failure and foot ulcers can meana constant fearfulness about the future as well asfrequent visits to hospitalwhichcan interfere with social and professional lives.

At Diabetes UK, we are encouraging doctors and healthcare professionals to look for symptoms of depression in patients who have Type 1 or Type 2 diabetes. A simple question like how do you feel about your diabetes? at the annual care planning session can start a conversation about low mood and depression. Diabetes UKs new Mood information prescriptionoutlines the key areas of a collaborative care management plan.

GPs are in the front line when it comes to managing patients with diabetes and they have an important role to play in helping people manage their depression as well. Of course, every individual needs a different approach. Some people with serious clinical depression may need to be referred to specialist services and have some kind of drug therapy to keep symptoms under control. For many people with diabetes who suffer with episodes of low mood, dietary and lifestyle changes such as taking regular exercise and getting enough sleep can help to ease the problem.

At Diabetes UK, we see a much greater scope for evidence-based talking therapies, such as Cognitive Behavioural Therapy for people who have diabetes and are suffering from depression. These therapies could be tailored towards the unique experience of people with diabetes and have a big impact on their quality of life.

Robin Hewings is head of policy for the charity Diabetes UK.

Read more from the original source:
Depression and diabetes - The Hippocratic Post (blog)

Posted in Diabetes | Comments Off on Depression and diabetes – The Hippocratic Post (blog)

Masons help Diabetes Center – Midland Daily News

Posted: April 6, 2017 at 8:46 pm

Past Master Jerry Chambers of Midland's Masonic Lodge, presents a check to Jill Chambers, diabetic educator of the Diabetes Center of MidMichigan Medical Center-Midland.

Past Master Jerry Chambers of Midland's Masonic Lodge, presents a check to Jill Chambers, diabetic educator of the Diabetes Center of MidMichigan Medical Center-Midland.

Masons help Diabetes Center

Past Master Jerry Chambers of Midlands Masonic Lodge presents a check to Jill Chambers, diabetic educator of the Diabetes Center of MidMichigan Medical Center-Midland. With Chambers is center staff member Ashley Shankool. In the back row, from left, are center staff members Maxine Guettler and Mary Jane Hoshaw, center manager. Also looking on are Lodge Senior Warden Tom Sova and Lodge Steward Mike Palmer. This years donation is the 16th annual donation that Centre Lodge No. 273 has made to the diabetes center. The funds are raised each year by holding a benefit spaghetti dinner that is open to the public. These funds are then partly matched by the Michigan Masonic Charitable Foundation helping to provide a significant donation. The center uses the money to provide scholarships to individuals who need the Diabetes Center services but are uninsured or under insured. These include diabetic adults, as well as pregnant women who are experiencing diabetic medical concerns.

Read more:
Masons help Diabetes Center - Midland Daily News

Posted in Diabetes | Comments Off on Masons help Diabetes Center – Midland Daily News

Mountain Ridge pitcher Tommy Lowe battles elbow, diabetes on way back to the mound – AZCentral.com

Posted: April 6, 2017 at 8:46 pm

Tommy Lowe, 18, a pitcher for the Mountain Ridge High School baseball team in Glendale, holds on to dreams of playing in college after discovering that he has Type 1 diabetes. He has received a scholarship from New Mexico State University.

Tommy Lowe, 18, is a pitcher for Mountain Ridge High School in Glendale, who found out he has Type 1 diabetes. He practices his pitching motions at the school, Tuesday, April 4, 2017.(Photo: Tom Tingle/azcentral sports)

Tommy Lowes senior season stat line coming into the week was two innings pitched, four strikeouts and a 10.50 earned run average.

But hell take that, knowing this is just the beginning of a final year at Glendale Mountain Ridge that appeared lost a month ago when he was diagnosed with Type 1 diabetes and was down to 138 pounds on his 6-foot-2 frame.

An All-Arizona pitcher last season when he won nine games, had a 1.84 ERA and won two state tournament games on his teams run to the 6A final, Lowe has seven regular-season games and the playoffs still to make it memorable.

Lowe wasnt sure hed take the mound at all after he found out he had diabetes while treating a stretched ulna nerve in his right elbow.

At school, there is a girl in one of my classes who has diabetes, Lowe said. She was just messing around and said, Hey, let me test your blood. So she tested my blood and it wouldnt read on her monitor. And shes like, Thats either too low or youre above 700, and Im like, What?

I didnt feel bad. Nothing felt different. I went to the doctor for my arm that day. And we told him about it. So he goes, All right, for precautionary, lets check your blood. He reads it and he goes to me, You need to go to the hospital right now. Your reading is off our charts, and theirs goes up to 700, as well.

Lowe said that he had been up to over 170 pounds, but when he went to the hospital, his weight was 138.

He said he is back up to 165 now.

But its been a slow climb back to the mound.

He has to regularly monitor his blood-sugar levels. He has learned to give himself insulin shots each day, injected into his stomach. He has to make sure he doesnt go above 75 grams of carbohydrates a day. He cant drink soda with sugar anymore.

I got a diet soda in the dugout right now, he says, because that has zero carbs.

I used to drink a lot of soda. Im drinking diet cherry Pepsi now.

Lowe said the insulin has helped him regain weight, but its been a season-long adjustment, not only trying to get his elbow healthy but keeping the diabetes under control.

When I first got on insulin and my blood sugar was leveling out, or at least trying to, Id be up and down a lot. When my blood sugar gets really high, my vision gets super blurry. I never had a problem with my vision before. Sometimes, Ill be out here wearing cheaters, because I cant get a prescription, because it changes every 20 minutes.

SPORTS AWARDS:List of azcentral.com Sports Awards Athletes of the Week, Month

Lowe has had his emotional ups and downas he watched helplessly from the dugout, as junior left-hander Matthew Liberatore (5-0, 0.68 ERA) has taken over the ace role on the staff.

Lowe, who logged 57 innings and faced 255 batters, throwing what he said he believes was 1,100 pitches his junior season, felt pain in his pitching elbow during a winter game.

He said the injury is in the ulna nerve. He said there is no tear, no need for surgery. It is stretched/strained, Lowe said.

The diabetes, his father, Floyd, said, has made the elbow slower to recover.

Its one of those things that if he did not have diabetes, his body would have already healed, said Floyd, a teacher at Glendale Community College who is retired from law enforcement. We didnt know that. Thats why the arm has been a problem.

Lowe felt invincible his first three years in high school. He pitched 47 innings his sophomore year on varsity, going 5-2 with a 2.53 ERA.

I always had a rubber arm, I could throw forever, Lowe said.

Since he was finally medically cleared to pitch last week, he has been ordered to throw no breakingpitches, only fastballs and change-ups. One of his big out-pitches was his slider. But this he feels will make him a more cerebral pitcher, relying on location and change of speed and pitching angles in his windup.

Coach Lance Billingsley said he is hoping that Lowe will be healthy enough to start a game as the playoffs near.

Lowe was clocked at 84-85 mph in his outing last week, when he gave up four hits and three runs in an inning in a 4-2 loss to Glendale Apollo. Last season, he was clocked in the high 80s.

He pitched for the Sun Belt team in the summer. He threw some for Mountain Ridge in fall and winter leagues.

I think his body wasnt recovering and he was pushing it physically, Billingsley said. By any account, hes lucky to even be here. For us to worry about him pitching, thats minute compared to what hes gone through.

Whats more important for him and his future is to be healthy enough to pitch next year.

Last year, Lowe accepted what he calls basically a full-ride from New Mexico State, in order to help his twin sister, Beth, become a certified nursing assistant. With almost all of his college expenses taken care of, thats relief for his parents, who can focus on helping Beth get through college.

About a foot shorter than her brother, Beth goes to Mountain Ridge in the morning and takes nursing classes in the afternoon, getting straight As, to get a jump on her career.

Hes proud of his sister, Floyd Lowe said. Being in the spotlight in baseball, he could think, Im the man. But he respects what she is doing.

Lowe isnt giving up on his senior season.

He is hoping to make an impact in state. By then, he believes he will be starting, his velocity will be up, and hell be getting hitters out.

Im getting stronger, getting better, he said.

Suggest human interest stories to Richard Obert at richard.obert@arizonarepublic.com or 602-316-8827. Follow him at azc_obert

Visit link:
Mountain Ridge pitcher Tommy Lowe battles elbow, diabetes on way back to the mound - AZCentral.com

Posted in Diabetes | Comments Off on Mountain Ridge pitcher Tommy Lowe battles elbow, diabetes on way back to the mound – AZCentral.com

Stem Cells May Offer Hope for Autism, Study Finds – wnep.com

Posted: April 6, 2017 at 1:47 am

ROCKLEDGE, Fla. Gracie Gregory smiles beneath her brilliant blue eyes. Shes sitting on her mothers lap, next to her older sister, Ryleigh, who boasts about Gracie being very sweet and kind.

It wasnt always so. Just a couple years ago, Ryleigh, 11, was scared of her sister when shed throw tantrums and screaming fits.

She wouldve fought and kicked, Ryleigh says, noting that it wouldnt have been possible to sit like this next to Gracie.

Why was she scared of her sister?

Because of the kicking.

Gracie, 7, interrupts: I dont even remember it.

We do, says her mother, Gina Gregory.

Gracie has autism, a condition that affected nearly every aspect of her familys life after she was diagnosed at 2. But a new study is offering hope for the Gregorys and families like them.

Gracie was one of 25 children who took part in the first-of-its-kind study at Duke University in Durham, North Carolina. The goal: to see whether a transfusion of their own umbilical cord blood containing rare stem cells could help treat their autism.

The results were impressive: More than two-thirds of the children showed reported improvements. A larger second trial is underway, one its researchers hope will lead to long-term treatment for children with autism.

Skeptics say there are too many unanswered questions to get excited. Even Duke researchers acknowledge as much. The initial trial, published Wednesday in the journal Stem Cells Translational Medicine, was a safety study, not a controlled, double-blind study with definitive proof of positive results. This study was open-label, meaning everyone the doctors and the families knew that the therapy was being administered.

But for the Gregorys, the change in their daughter has been monumental.

Gone are the days of Gracie throwing fits in long lines at Disney World or during dinner at restaurants. When a tantrum intruded on family outings, her mom and dad wished they had T-shirts that said My kid has autism to ward off judgmental stares.

During autism therapy sessions, Gracie would kick, scream, spit and hit at her occupational therapist. It was horrible to try to get her to sit there, her mother says.

Even just brushing her teeth or combing her hair could set her off.

Gracie, then 5, was on the mild to moderate autism scale, but her parents say the disorder consumed about 75% of their daily routine. After her participation in the study, that figure has been reduced to a mere 10%.

On a scale of 1 to 10, they rate her improvement around an 8 or 9; its been that dramatic. Shes even begun attending a regular school and thriving there, something her parents never thought possible. Shed been in various specialized school programs, and nothing was the proper fit.

Are Gracies changes a result of the cord blood transfusion stimulating her brain? Or did her brain just mature as she got older? Could it be that her parents were subconsciously determined to magnify her improvements, given all their family had been through?

Those are questions the Gregorys still ask. But they do know that their daughters transformation appeared to begin about six months after her transfusion in January 2015 and has continued ever since.

Her fathers favorite adjustment is her newfound affection. Instead of shunning hugs, she now welcomes an embrace.

We will say we dont think its cured her. You still see some of the small idiosyncrasies that she does have, says her father, Wade Gregory. But again, I think its supercharged her learning curve. Its pushed her to do things she normally wouldnt do.

Her mother adds, She got better, and were just thankful for that whether it be the stem cells or not. Were just thankful for what changes have happened.

Billions of cells

Dr. Joanne Kurtzberg shows off a freezer deep inside the bowels of the Carolinas Cord Blood Bank at Duke University Medical Center. Known as a thermogenesis freezer, it stores up to 3,640 units of cord blood left over from babies umbilical cords and placenta at minus 196 degrees Celsius.

Each unit is designated by labels with specially designed adhesive to withstand extremely cold temperatures for decades. There are 14 cord blood freezers in all.

It is the cord blood in those freezers stored or donated by parents in case a serious illness develops thats at the cutting edge of this research.

Kurtzberg, who heads the Robertson Clinical and Translational Cell Therapy Program, has teamed up with Dr. Geraldine Dawson, director of the Duke Center for Autism and Brain Development.

Both saw a great need for medical advances to help treat children with autism. An estimated one in every 68 children in America has some form of autism spectrum disorder, according to the Centers for Disease Control and Prevention.

About 30% never learn to speak, and many children even with early behavioral interventions still struggle to adapt. There also are no FDA-approved medications that improve the core symptoms of autism.

I was very interested in collaborating with people here at Duke who could offer medical approaches that could enhance neuroplasticity, or the brains ability to respond to treatment, Dawson says.

Thats where Kurtzberg comes in. Over the past two decades, she had seen children with inherited metabolic disorders be treated with cord blood after receiving high doses of chemotherapy.

Weve been able to show that with some of these diseases, a cord transplant rescues them from death and also improves their neurologic outcome, she says.

She began wondering: Could cord blood help other children?

About a decade ago, her laboratory began clinical tests of children with cerebral palsy whose parents had banked their cord blood. Again, they saw positive results. And in some of those children who had autistic tendencies, they saw autistic symptoms improve. Another spark went off: What if they tested cord blood specifically for autism?

The safety trial began a little over a year and a half ago. Not only did it find cord blood to be safe, but 70% of the 25 children, age 2 to 6, had behavioral improvements as described by their parents and tracked by the Duke researchers. The research is largely funded by a $40 million donation from the Marcus Foundation, a nonprofit created by Home Depot co-founder Bernie Marcus.

The children traveled to Duke three times over the course of a year. They underwent a series of evaluations such as autism assessments, MRIs and EEGs to track their brain activity. On the first trip, the children received the cord blood infusion along with the intense evaluations. Each child received 1 billion to 2 billion cells, given through an IV in their arms or legs. At six months and then a year later, the children returned for more tests and observations.

Some children, who were not speaking very much, had big increases in their vocabulary and their functional speech, Kurtzberg says. Many children were able to attend to play and have meaningful communication in a way that they werent before. Some children had less repetitive behaviors than they did when they came onto the study.

Adds Dawson, The study was very encouraging. We did see positive results. However, it did not have a comparison group, which is very important in establishing whether a treatment is actually effective.

Both researchers cant stress that enough: that although theyre cautiously optimistic about the results, they want the science to play out. They are now in the midst of the definitive trial on whether cord blood can treat autism a double-blind, placebo-controlled trial involving 165 autistic children, ranging in age from 2 to 8. The FDA has oversight of the study.

During the phase II study, the children on their first visit receive a cord blood infusion either their own or from a donor or they get a placebo. They also undergo a battery of assessment tests and brain monitoring.

On their second visit six months later, the children receive a second infusion with whatever preparation they did not receive the first time and undergo more evaluations. The order of the infusions is not known. Researchers will monitor them for the next year for any sign of behavioral improvements.

Its known as a crossover trial, in which each subject gets the treatment and the placebo but in a different order. Researchers say it would have been nearly impossible to find participants if parents knew that their children might not receive an infusion.

How groundbreaking would it be if the trial shows similar results to the safety study?

If we can show that receiving an infusion of cord blood is more effective for improving social behavior than the placebo, Dawson says, then this will be game-changing.

Kurtzberg adds, Well be extraordinarily encouraged if the second trial shows that the cells benefit children when the placebo does not. We will consider that a breakthrough.

Both researchers were shaped early in life by the struggles families face raising autistic children. As a teen, Dawson babysat twins with autism who lived across the street. It was just an inspiration to devote my career to improving the lives of people with autism, she says.

Kurtzberg was similarly affected. When she was a junior in college, she would visit a girl with severe autism and play with her as a means of behavioral intervention. The family still writes to me, she says.

It is for this reason their longtime devotion to families raising children with autism that both issue a heap of caution. Although theyre excited about the results of the first study, Kurtzberg says, we dont want to mislead people and claim its working before we have definitive proof.

Adds Dawson, Its important for parents who might hear about cord blood as a potential treatment for autism to know that we are working very hard to know the answer to that question. We arent there yet.

Cautious optimism

Kurtzberg has a hypothesis about what may be happening: that certain immune cells within the cord blood are crossing the blood-brain barrier and altering brain connectivity while also suppressing inflammation, which may exist with autism.

I feel more confident now because of our (cerebral palsy) study, which preceded this study and does show benefits, Kurtzberg says.

Dr. Arnold R. Kriegstein, director of the stem cell center at the University of California, San Francisco, says that he hopes there will be breakthrough treatment for children with autism but that much more needs to be known before this will become a reality.

One has to be very careful when interpreting results that havent come from properly controlled, double-blind studies, he said. All I can say is that it would be wonderful if this treatment was effective, but one has to be very cautious before reaching any conclusions.

Even without a placebo effect, he says, many factors could have resulted in an improved outcome in the first study: The growing children could have acquired skills simply through maturation, possibly enhanced by occupational therapy, and their parents may have clung to positive gains, creating a biased outcome.

Thomas Frazier II, chief scientific officer of the advocacy group Autism Speaks, said the results of the initial study were encouraging but that more work needs to be done before the public gets excited. Its too early to get hopeful. Too early to change behavior, he said. I hope people dont go out and spend money on banking cord blood as a result [of this trial].

Kriegstein of UCSF also wonders whether cord blood is really stimulating cells in the brain and creating new connections. There are so many unanswered questions about what might be going on here, it becomes very difficult to evaluate the proposed mechanism, he said.

The question remains: How do these cells injected intravenously wind up in the brain, how do they target the appropriate brain regions, and what are they doing that could improve brain function?

I forgot how bad it was

An 8-year-old boy with autism sits at a table in a room within Dukes Center for Autism and Brain Development. Clinical research specialist Michelle Green watches from behind a two-way mirror. Two cameras in the room feed computer monitors, allowing her to further analyze his behavior.

Dr. Lauren Franz, a clinician, works with the boy in the room.

What kind of things make you feel threatened or anxious? she asks.

Like when Im done with a test, the boy says.

How does it feel when youre frightened or anxious? How does that feel?

Like pretty weird, he says.

The boy is participating in the second trial, and hes returned for his six-month assessment and second infusion. Researchers dont know which infusion he received first: the cord blood or the placebo.

But they track, record and monitor the slightest of details. Although it might seem like an innocuous conversation, researchers will compare the results with those of his first visit and any follow-ups. Was he able to sit still at the table before? Could he articulate his thoughts? Did he talk before the study? Has he improved?

At the Gregorys home in Florida, Gracies parents remember when she went through those same tests. The best investment they ever made, they say, was the $2,000 spent on banking her cord blood. At the time, it was just a precaution; her autism diagnosis didnt come until three months after her second birthday.

They know the desperation of families raising a child with autism of longing for their daughter to have a shot of normalcy in life. You cant quantify it. You cant measure it. You want to see your child succeed, her father says.

Mom and Dad recently watched old home videos, of Gracie singing inaudibly, of her covering her ears when Happy Birthday was sung for her third birthday, of showing no emotion on Christmas when she was 2. I forgot how bad it was, her mother says.

They hope the current study leads to similar successes and results in breakthrough treatment for autistic children everywhere.

Excerpt from:
Stem Cells May Offer Hope for Autism, Study Finds - wnep.com

Posted in California Stem Cells | Comments Off on Stem Cells May Offer Hope for Autism, Study Finds – wnep.com

Page 1,612«..1020..1,6111,6121,6131,614..1,6201,630..»